338 related articles for article (PubMed ID: 38675402)
1. The Therapeutic Trip of Melatonin Eye Drops: From the Ocular Surface to the Retina.
Rusciano D; Russo C
Pharmaceuticals (Basel); 2024 Mar; 17(4):. PubMed ID: 38675402
[TBL] [Abstract][Full Text] [Related]
2. Melatonin: Implications for Ocular Disease and Therapeutic Potential.
Scuderi L; Davinelli S; Iodice CM; Bartollino S; Scapagnini G; Costagliola C; Scuderi G
Curr Pharm Des; 2019; 25(39):4185-4191. PubMed ID: 31724508
[TBL] [Abstract][Full Text] [Related]
3. Role of melatonin in the eye and ocular dysfunctions.
Lundmark PO; Pandi-Perumal SR; Srinivasan V; Cardinali DP
Vis Neurosci; 2006; 23(6):853-62. PubMed ID: 17266777
[TBL] [Abstract][Full Text] [Related]
4. Influence of Circadian Rhythm in the Eye: Significance of Melatonin in Glaucoma.
Martínez-Águila A; Martín-Gil A; Carpena-Torres C; Pastrana C; Carracedo G
Biomolecules; 2021 Feb; 11(3):. PubMed ID: 33668357
[TBL] [Abstract][Full Text] [Related]
5. State of the art clinical efficacy and safety evaluation of N-acetylcarnosine dipeptide ophthalmic prodrug. Principles for the delivery, self-bioactivation, molecular targets and interaction with a highly evolved histidyl-hydrazide structure in the treatment and therapeutic management of a group of sight-threatening eye diseases.
Babizhayev MA; Kasus-Jacobi A
Curr Clin Pharmacol; 2009 Jan; 4(1):4-37. PubMed ID: 19149498
[TBL] [Abstract][Full Text] [Related]
6. Melatonin in the eye: implications for glaucoma.
Lundmark PO; Pandi-Perumal SR; Srinivasan V; Cardinali DP; Rosenstein RE
Exp Eye Res; 2007 Jun; 84(6):1021-30. PubMed ID: 17174303
[TBL] [Abstract][Full Text] [Related]
7. A Topical Formulation of Melatoninergic Compounds Exerts Strong Hypotensive and Neuroprotective Effects in a Rat Model of Hypertensive Glaucoma.
Dal Monte M; Cammalleri M; Amato R; Pezzino S; Corsaro R; Bagnoli P; Rusciano D
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291737
[TBL] [Abstract][Full Text] [Related]
8. Melatonin as a therapeutic tool in ophthalmology: implications for glaucoma and uveitis.
Rosenstein RE; Pandi-Perumal SR; Srinivasan V; Spence DW; Brown GM; Cardinali DP
J Pineal Res; 2010 Aug; 49(1):1-13. PubMed ID: 20492443
[TBL] [Abstract][Full Text] [Related]
9. Protective effects of melatonin in experimental free radical-related ocular diseases.
Siu AW; Maldonado M; Sanchez-Hidalgo M; Tan DX; Reiter RJ
J Pineal Res; 2006 Mar; 40(2):101-9. PubMed ID: 16441546
[TBL] [Abstract][Full Text] [Related]
10. The use of benzalkonium chloride in topical glaucoma treatment: An investigation of the efficacy and safety of benzalkonium chloride-preserved intraocular pressure-lowering eye drops and their effect on conjunctival goblet cells.
Nagstrup AH
Acta Ophthalmol; 2023 Dec; 101 Suppl 278():3-21. PubMed ID: 38037546
[TBL] [Abstract][Full Text] [Related]
11. Ophthalmic formulations of the intraocular hypotensive melatonin agent 5-MCA-NAT.
Andrés-Guerrero V; Alarma-Estrany P; Molina-Martínez IT; Peral A; Herrero-Vanrell R; Pintor J
Exp Eye Res; 2009 Mar; 88(3):504-11. PubMed ID: 19056382
[TBL] [Abstract][Full Text] [Related]
12. Distribution of topical ocular nepafenac and its active metabolite amfenac to the posterior segment of the eye.
Chastain JE; Sanders ME; Curtis MA; Chemuturi NV; Gadd ME; Kapin MA; Markwardt KL; Dahlin DC
Exp Eye Res; 2016 Apr; 145():58-67. PubMed ID: 26474497
[TBL] [Abstract][Full Text] [Related]
13. N-Acetylcarnosine sustained drug delivery eye drops to control the signs of ageless vision: glare sensitivity, cataract amelioration and quality of vision currently available treatment for the challenging 50,000-patient population.
Babizhayev MA; Burke L; Micans P; Richer SP
Clin Interv Aging; 2009; 4():31-50. PubMed ID: 19503764
[TBL] [Abstract][Full Text] [Related]
14. The role and therapeutic potential of melatonin in age-related ocular diseases.
Crooke A; Huete-Toral F; Colligris B; Pintor J
J Pineal Res; 2017 Sep; 63(2):. PubMed ID: 28658514
[TBL] [Abstract][Full Text] [Related]
15. A Clinical, Pharmacological, and Formulation Evaluation of Melatonin in the Treatment of Ocular Disorders-A Systematic Review.
Romeo A; Kazsoki A; Musumeci T; Zelkó R
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612812
[TBL] [Abstract][Full Text] [Related]
16. A review on recent drug delivery systems for posterior segment of eye.
Nayak K; Misra M
Biomed Pharmacother; 2018 Nov; 107():1564-1582. PubMed ID: 30257375
[TBL] [Abstract][Full Text] [Related]
17. A hypotonic gel-forming eye drop provides enhanced intraocular delivery of a kinase inhibitor with melanin-binding properties for sustained protection of retinal ganglion cells.
Kim YC; Hsueh HT; Shin MD; Berlinicke CA; Han H; Anders NM; Hemingway A; Leo KT; Chou RT; Kwon H; Appell MB; Rai U; Kolodziejski P; Eberhart C; Pitha I; Zack DJ; Hanes J; Ensign LM
Drug Deliv Transl Res; 2022 Apr; 12(4):826-837. PubMed ID: 33900546
[TBL] [Abstract][Full Text] [Related]
18. Bioactivation antioxidant and transglycating properties of N-acetylcarnosine autoinduction prodrug of a dipeptide L-carnosine in mucoadhesive drug delivery eye-drop formulation: powerful eye health application technique and therapeutic platform.
Babizhayev MA
Drug Test Anal; 2012 Jun; 4(6):468-85. PubMed ID: 21416634
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of topical dexamethasone eye drops in preventing ocular inflammation and cystoid macular edema following uncomplicated cataract surgery with or without injection of a single dose perioperative subtenon triamcinolone acetonide.
Karasu B; Kesim E; Kaskal M; Celebi ARC
Cutan Ocul Toxicol; 2022 Dec; 41(4):310-317. PubMed ID: 36308286
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers and special features of oxidative stress in the anterior segment of the eye linked to lens cataract and the trabecular meshwork injury in primary open-angle glaucoma: challenges of dual combination therapy with N-acetylcarnosine lubricant eye drops and oral formulation of nonhydrolyzed carnosine.
Babizhayev MA
Fundam Clin Pharmacol; 2012 Feb; 26(1):86-117. PubMed ID: 21883446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
